Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Abroad (travel likely)Recruiting
Conditions
Non-Small Cell Carcinoma of Lung, TNM Stage 4 · Non-Small Cell Lung Cancer · EGFR Gene Mutation · ALK Gene Mutation · ROSE Cluster 1 · BRAF V600E
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Colorado, Cancer Center, Aurora, Colorado, United States
Contact: Principal Investigator (Erin Schenk)
Study leads
Erin Schenk
Principal Investigator
University of Colorado, Denver